Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated November 11, 2025, discloses transactions in company shares by board members, executives, and associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The filing serves as a regulatory notification of insider trading activity rather than a financial performance report.
Key Financial Metrics
The filing text does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures present relate to specific share transactions:
- Acquisition: 18,634 shares acquired at a price of DKK 0.00 (recruitment package).
- Sale: 8,160 shares sold at DKK 297.95 per share, totaling DKK 2,431,301.74.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing solely details the change in share ownership for Executive Vice President, US Operations, David Moore, on November 10, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a standard disclosure of insider trading activity.
Key Facts for Investor Verification
- Executive Involved: David Moore, Executive Vice President, US Operations.
- Transaction Date: November 10, 2025.
- Net Share Change: Net acquisition of 10,474 shares (18,634 acquired minus 8,160 sold).
- Transaction Venues: Acquisition occurred outside a trading venue; sale occurred on Nasdaq Copenhagen.
- Company Profile: Novo Nordisk employs approximately 78,400 people in 80 countries and markets products in around 170 countries.